The North America locally advanced pancreatic cancer market reached US$607.9 million in 2024 and is projected to grow at a 6.7% CAGR, hitting US$1.09 billion by 2033, bolstered by rising incidence rates and wider uptake of combined chemo (FOLFIRINOX, Gem/Nab-Paclitaxel) and emerging immunotherapy protocols https://www.datamintelligence.com/research-report/north-america-locally-advanced-pancreatic-cancer-market